KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EBT (2016 - 2025)

Historic EBT for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $1.0 billion.

  • Regeneron Pharmaceuticals' EBT rose 893.43% to $1.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.2 billion, marking a year-over-year increase of 943.12%. This contributed to the annual value of $5.2 billion for FY2025, which is 943.12% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its EBT stood at $1.0 billion for Q4 2025, which was up 893.43% from $1.8 billion recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' EBT registered a high of $3.8 billion during Q2 2021, and its lowest value of $700.7 million during Q1 2024.
  • Moreover, its 5-year median value for EBT was $1.2 billion (2021), whereas its average is $1.4 billion.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' EBT soared by 30840.13% in 2021, and later plummeted by 7433.38% in 2022.
  • Quarter analysis of 5 years shows Regeneron Pharmaceuticals' EBT stood at $2.5 billion in 2021, then crashed by 47.08% to $1.3 billion in 2022, then fell by 13.37% to $1.1 billion in 2023, then fell by 16.51% to $958.1 million in 2024, then rose by 8.93% to $1.0 billion in 2025.
  • Its last three reported values are $1.0 billion in Q4 2025, $1.8 billion for Q3 2025, and $1.5 billion during Q2 2025.